MEK-162 Binimetinib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：MEK-162 Binimetinib	Purity：98% min
CAS NO：606143-89-9	Solubility：DMSO : 50 mg/mL (113.32 mM)
Molecular Formula：C₁₇H₁₅BrF₂N₄O₃	Package：Package according to customer requirements
Molecular Weight：441.227	Storage：Store at -20℃

Quality control

COA

Remarks

Binimetinib, also known as MEK162 (ARRY-162), is an oral, highly selective MEK inhibitor. In preclinical studies, MEK162 showed significant antitumor activities in cell lines and animal models. MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.

MEK Inhibitor Related Products:

Selumetinib; Mirdametinib (PD0325901); Trametinib; PD184352 (CI-1040); PD98059; BIX02189; U0126-EtOH; Pimasertib; BIX02188; TAK-733; SL327; Refametinib; GDC-0623; RO5126766 (CH5126766); Cobimetinib; APS-2-79 hydrochloride ; AZD8330

References

[1]. J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.

[2]. Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123(6), 2551-2563.

[3]. Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6(39):42183-96.